Phase II proof-of-concept study of ALS 2158 in combination with antivirals (all oral interferon-free regimens) in patients with hepatitis C.
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2012
At a glance
- Drugs ALS 2158; Antivirals
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 26 Sep 2012 Status changed from planning to discontinued prior to enrolment.
- 22 Feb 2012 Trial initiation is planned for the second half of 2012, according to a Vertex Pharmaceuticals media release
- 11 Jan 2012 New trial record